Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Agios Pharmaceuticals, Inc.
Type
Public
Traded as NASDAQ: AGIO
Industry Pharmaceuticals
Founded 2008 (2008)
Headquarters Cambridge, Massachusetts, United States
Key people
David Schenkein (CEO)
Website agios.com
Footnotes / references
Foundation

Agios Pharmaceuticals is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Among the proteins under investigation by the company are IDH1 and IDH2. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.

In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.

In May 2016, the company announced it would launch partnership with Celgene, developing metabolic immuno-oncology therapies. The deal could net more than $1 billion for Agios.

In April 2017, the company raised $250 million in a new stock offering in anticipation of FDA approval for its first cancer drug.

As of April 2017, Agios' CEO was David Schenkein.

Agios was established as a private company and converted to a public company with its initial public offering in July 2013 and subsequent listing on NASDAQ.


Investment goal date:
Dividends reinvested
Agios Pharmaceuticals, Inc. AGIO report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-05
--
--
Q4 2017
2018-02-19
--
--
Q4 2017
2018-02-14
--
--
Q3 2017
2017-11-01
0.0000
0.0000
Q2 2017
2017-08-08
-1.7800
-1.7800
Q1 2017
2017-05-04
-1.5600
-1.5600
Q4 2016
2017-02-16
-1.3400
-1.3400
Q3 2016
2016-11-03
-1.6300
-1.6300
Q2 2016
2016-08-04
-1.4700
-1.4700
Q1 2016
2016-05-05
-0.6100
-0.6100
Q4 2015
2016-02-18
-1.0800
-1.0800
Q3 2015
2015-11-05
-1.0700
-1.0700
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
BALYASNY ASSET MANAGEMENT LLC
869122
BlackRock Fund Advisors
917140
BlackRock Inc.
2167074
BlackRock Institutional Trust Company, N.A.
870876
CAPITAL GUARDIAN TRUST CO
934879
Capital International Investors
2804527
Clearbridge Investments, LLC
1538912
Flagship Ventures 2007 General Partner LLC
1930369
Flagship Ventures Fund 2007, L.P.
1930369
FMR LLC
6331747
PRICE T ROWE ASSOCIATES INC /MD/
1402174
Redmile Group, LLC
902578
STATE STREET CORP
1205746
Vanguard Group, Inc
2597391
WELLINGTON MANAGEMENT CO LLP
5893596
Major Shareholders
Name Relationship
Total Shares
Holding stocks
MARAGANORE JOHN
0.1400% (49764)
AGIO / ALNY / BLUE / RGLS /
STARR KEVIN P
0.5400% (184386)
AGIO / ALNY / SAGE /
Arch Venture Fund VII LP
8.9600% (3088590)
Tessier-Lavigne Marc
0.2900% (101009)
AGIO / PFE / REGN /
Cole Douglas G.
0.0100% (2778)
AGIO / RCPT / TTPH /
Flagship Ventures Fund 2007, L.P.
5.6000% (1930369)
AGIO / EBIO / RCPT /
Celgene European Investment Co LLC
5.3900% (1856353)
AGIO / CELG / EPZM /
Cantley Lewis Clayton Jr.
0.2400% (83434)
AGIO /
Higgons John Duncan
0.3500% (120834)
AGIO /
% ()